Fendx Technologies, Inc. · CSE:FNDX
Fendx Technologies — Investor Presentation (January 2025)
23 slides from Fendx Technologies's investor presentation, January 2025
Slide 1: Innovating Surface Protection Products to Reduce the Spread of Pathogens
Innovating Surface Protection Products to Reduce the Spread of Pathogens Committed to Making Lives Safer CSE: FNDX | OTCQB: FDXTF | FSE: E8D JANUARY 2025
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface and coating
Slide 3: Advancing Novel Technologies for Effective Pathogen Control
ADVANCING NOVEL TECHNOLOGIES FOR EFFECTIVE PATHOGEN CONTROL Nanotechnology*: developing film & spray formats that repel pathogens, keeping surfaces clean, and nano-coating of catheters Eco-Friendly Sponge**: sustainable, reusable sponge for cleaning surfaces and for development as a drug delivery de
Slide 4: Silent Pandemic: The Alarming Reality of Pathogens
Silent Pandemic: The Alarming Reality of Pathogens • Rise of antibiotic-resistant (AMR) pathogens is a growing global healthcare threat, posing significant healthcare and economic issues • 1.27 M deaths globally attributed to AMR in 2019 1 • AMR could surpass cancer as leading cause of death by 2050
Slide 5: AMR: Hidden Threats in Everyday Places
AMR: Hidden Threats in Everyday Places SPORTS / MALLS / From high-touch ARENAS surfaces to water systems and HVAC HOTELS / Where SCHOOLS units, pathogens RESTAURANTS / pathogens HOUSEHOLDS CAFES can reside can be found everywhere RAILWAYS / HEALTHCARE / AIRPORTS / LABORATORIES CRUISE LINES / BUSES /
Slide 6: Current Hygiene Practices: Failing to Halt the Rise of AMR
Current Hygiene Practices: Failing to Halt the Rise of AMR • Over-prescribing and misuse of antibiotics accelerates the development of resistance • Improper or inconsistent cleaning can facilitate their transmission Additional innovative solutions are needed to contribute to reducing the spread of A
Slide 7: Novel Eco-Friendly Sponge for Surface Cleaning and Skin Drug Delivery
Novel Eco-Friending Sponge for Surface Cleaning and Skin Drug Delivery • LOI to acquire IP and BioFoam® trademark, and enter into a supply agreement for eco-friendly sponge to clean surfaces and as a drug delivery device in would care market 1 • Technology currently used to detect / remove oil and c
Slide 8: Household Sponge Market Offers Significant Opportunity
Household Sponge Market Offers Significant Opportunity for Eco-Friendly Sponge Key Differentiators of the Eco-Friendly Sponge: Estimated North American • Innovative Technology: resistant to bacterial growth and odors vs. traditional sponges sponge market revenue in 2033 (USD)1 • Sustainable: washabl
Slide 9: Eco-Friendly Sponge: Skin Drug Delivery Use
Eco-Friendly Sponge: Skin Drug Delivery Use • FDA 501(k) approved skin lotion impregnated in sponge to protect against chemical burns • Cleared based on studies conducted by the U.S. Department of the Army • PCT filed entitled: Open-Cell Foam Based Wound Treatment - to be acquired by FendX pursuant
Slide 10: Unique Nanotechnology to Protect Surfaces
Unique Nanotechnology Protected with to Protect Surfaces Nano-Coating Provides immediate & continuous protection of surfaces reducing adhesion of bacteria and virus >98%1,2, 3 When a contaminated hand touches Unprotected a nano-coated protected surface, the contamination tends to stay on the hand an
Slide 11: REPELWRAP Film
Adhesive backing to easily REPELWRAP Film apply to high touch surfaces Lead Nano-Coated Product in Development • >98% reduction in adhesion of a Covid-19 like virus, E. coli, B. subtilis and MRSA1,2 • Target markets: healthcare and other high-touch, high traffic venues (i.e., transportation, schools
Slide 12: Nano-Particles Spray Coating
Nano-Particles Spray Coating Offers Additional Approach to Applying a Surface Protection Coating • 99.9% reduction in MRSA and Pseudomonas aeruginosa and 98% for Phi6 (a virus)1 • Expected to be easier to apply and expand applications Schematic illustration of nanoparticle suspension • Completing fo
Slide 13: REPELWRAP Film and Nano-Particle Suspension Competitive Landscape
REPELWRAP Film and Nano-Particle Suspension Competitive Landscape Metal- REPELWRAP Film Liquid Containing** and & Spray* Disinfectants Photo-Activated Films Repels bacteria, viruses, +++ - - blood and liquids Instantly protects +++ +++ + 24-hour protection +++ - +++ Does not promote bacterial +++ +
Slide 14: Antimicrobial & Antiviral Nano-Coating: A Significant Opportunity
Antimicrobial & Antiviral Nano-Coating: A Significant Opportunity Estimated global market revenue in 2031 (USD) 1 ~$1.85 Bn ~ 8% CAGR (2024-2031) FendX has signed LOI with Sinelabs who will distribute FendX future film & spray in Sources: 1. https://www.futuremarketsinc.com/the-global-market-for-ant
Slide 15: Nano-Coating Foley Catheters
Nano-Coating Foley Catheters In Development to Reduce Infections Estimated global market revenue in 2033 (USD) 1 • ~1 M foley catheter-associated infections at medical cost US$0.3-$2.3 Bn 2,3 ~$2.6 Bn • >96% reduction in attachment of E. coli after 24-48 hours of flow exposure 4 • In prototype devel
Slide 16: Building A Robust Nano-Tech Patent Portfolio
Building A Robust Nano-Tech Patent Portfolio Omniphobic Surfaces with Hierarchical Methods of Making Omniphobic Materials with Structures, and Methods of Making and Uses Hierarchical Structures and Uses Thereof Thereof • US Patent Application Number # 18/683,578 • Chinese/ Macau Patent # ZL 20208005
Slide 17: Capital Light Model
Partner with contract manufacturers Capital Light LOI signed for Eco-friendly sponge supply agreement Model Secure licensing/distribution partners; FendX signed LOI with Sinelabs who will distribute FendX future products in overlapping target market As corporate sponsor, support McMaster in securing
Slide 18: FendX Share Structure
FendX Share Structure Share Structure as of December 31, 2024 Shares outstanding: 73,448,359 Options: 5,741,667 RSUs 593,334 Warrants: 18,954,320 Insider ownership < 20% CSE: FNDX | OTCQB: FDXTF | FSE:E8D JANUARY 2025/ 18
Slide 19: Proven Management Team
Proven Management Team Dr. Carolyn Myers MBA, PhD Rose Zanic CPA, CA Tash Yousuf BSc President, CEO & Director CFO & Corporate Secretary Sr. Operations Manager • Accomplished senior pharma executive with • Over 25 years of capital markets and • Expertise in project and operations extensive experienc
Slide 20: Board of Directors
Board of Directors Stephen Randall CPA, CGA • Senior financial manager and Director with over 40 years’ experience. • Served in senior financial roles with both private, publicly traded and start-up companies in the Independent Board Member manufacturing, telecommunications, technology, and medical
Slide 21: Advisors
Advisors • CEO and founder of US BioSolutions and the innovator of BioFoam® technology and trade secrets Scott Smith • Winner of Blueprint’s 2024 Impact Award for Positive Social Change Advisor • Inventor named on 25 patents for testing/remediation of water, surfaces, and air contaminated with dange
Slide 22: Company Highlights
Company Highlights • Focused on developing products in the infectious • Catheters coated with FendX’s nanotechnology in disease control area to protect surfaces from prototype development to reduce blood clot and bacteria and viruses bacterial biofilm formation • REPELWRAP film, FendX’s lead product
Slide 23: Thank You!
Thank You! investor@fendxtech.com / fendxtech.com CSE: FNDX | OTCQB: FDXTF | FSE:E8D JANUARY 2025/ 23
FendX Technologies — Investor Presentation (January 2025) on 6ix